Epigenomics (ECX) Ratios
Epigenomics Ratios
DE:ECX's free cash flow for Q? was ―. For the fiscal year, DE:ECX's free cash flow was increased by ― and operating cash flow was ―. See a summary of the company’s cash flow.
| Ratios | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|
| Liquidity Ratios | |||
| Current Ratio | 5.27 | 2.13 | 11.06 |
| Quick Ratio | 5.27 | 2.12 | 10.98 |
| Cash Ratio | 4.37 | 1.98 | 10.76 |
| Solvency Ratio | -0.24 | -1.99 | -0.79 |
| Operating Cash Flow Ratio | -11.85 | -2.37 | -1.94 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -10.31M | $ 5.13M | $ 21.17M |
| Leverage Ratios | |||
| Debt-to-Assets Ratio | 0.93 | 0.05 | 0.02 |
| Debt-to-Equity Ratio | 0.00 | 0.08 | 0.02 |
| Debt-to-Capital Ratio | 1.00 | 0.08 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 1.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 0.00 | 1.56 | 1.11 |
| Debt Service Coverage Ratio | 0.00 | -85.73 | -37.63 |
| Interest Coverage Ratio | 0.00 | -92.70 | -45.27 |
| Debt to Market Cap | 7.53 | 0.00 | 0.00 |
| Interest Debt Per Share | 13.93 | 1.19 | 0.91 |
| Net Debt to EBITDA | -3.46 | 0.82 | 11.65 |
| Profitability Margins | |||
| Gross Profit Margin | 83.19% | 75.26% | 97.81% |
| EBIT Margin | -1232.15% | -2468.25% | -38.01% |
| EBITDA Margin | -833.92% | -2313.81% | -31.26% |
| Operating Profit Margin | -1232.15% | -2484.74% | -37.95% |
| Pretax Profit Margin | -1316.81% | -2495.05% | -38.85% |
| Net Profit Margin | -1316.81% | -2479.18% | -39.14% |
| Continuous Operations Profit Margin | -1316.81% | -2479.18% | -39.14% |
| Net Income Per EBT | 100.00% | 99.36% | 100.75% |
| EBT Per EBIT | 106.87% | 100.41% | 102.38% |
| Return on Assets (ROA) | -34.75% | -75.85% | -9.84% |
| Return on Equity (ROE) | 0.00% | -118.21% | -10.98% |
| Return on Capital Employed (ROCE) | -33.79% | -111.81% | -10.45% |
| Return on Invested Capital (ROIC) | -33.79% | -107.86% | -10.41% |
| Return on Tangible Assets | -34.78% | -93.41% | -9.87% |
| Earnings Yield | -282.74% | -179.20% | -32.38% |
| Efficiency Ratios | |||
| Receivables Turnover | 0.96 | 5.39 | 84.97 |
| Payables Turnover | 0.22 | 0.03 | 0.27 |
| Inventory Turnover | 0.00 | 1.97 | 0.77 |
| Fixed Asset Turnover | 113.00 | 0.24 | 6.95 |
| Asset Turnover | 0.03 | 0.03 | 0.25 |
| Working Capital Turnover Ratio | 0.09 | 0.04 | 0.00 |
| Cash Conversion Cycle | -1279.51 | -10514.23 | -873.31 |
| Days of Sales Outstanding | 379.00 | 67.73 | 4.30 |
| Days of Inventory Outstanding | 0.00 | 185.54 | 472.35 |
| Days of Payables Outstanding | 1658.51 | 10767.50 | 1349.96 |
| Operating Cycle | 379.00 | 253.27 | 476.65 |
| Cash Flow Ratios | |||
| Operating Cash Flow Per Share | -6.69 | -14.78 | -7.41 |
| Free Cash Flow Per Share | -6.69 | -16.46 | -7.47 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -8.81 | -118.63 |
| Capital Expenditure Coverage Ratio | 0.00 | -8.81 | -118.63 |
| Operating Cash Flow Coverage Ratio | -0.48 | -14.30 | -9.03 |
| Operating Cash Flow to Sales Ratio | -16.85 | -24.79 | -0.67 |
| Free Cash Flow Yield | -361.73% | -199.54% | -55.84% |
| Valuation Ratios | |||
| Price-to-Earnings (P/E) Ratio | -0.35 | -0.56 | -3.09 |
| Price-to-Sales (P/S) Ratio | 4.66 | 13.83 | 1.21 |
| Price-to-Book (P/B) Ratio | 0.00 | 0.66 | 0.34 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.28 | -0.50 | -1.79 |
| Price-to-Operating Cash Flow Ratio | -0.28 | -0.56 | -1.81 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.00 | 0.00 |
| Enterprise Value Multiple | -4.02 | 0.22 | 7.78 |
| Enterprise Value | 11.36M | -2.49M | -15.09M |
| EV to EBITDA | -4.02 | 0.22 | 7.78 |
| EV to Sales | 33.52 | -5.12 | -2.43 |
| EV to Free Cash Flow | -1.99 | 0.19 | 3.60 |
| EV to Operating Cash Flow | -1.99 | 0.21 | 3.63 |
| Tangible Book Value Per Share | -0.01 | 8.84 | 39.37 |
| Shareholders’ Equity Per Share | 0.00 | 12.51 | 39.47 |
| Tax and Other Ratios | |||
| Effective Tax Rate | 0.00 | 0.01 | -0.01 |
| Revenue Per Share | 0.40 | 0.60 | 11.07 |
| Net Income Per Share | -5.23 | -14.78 | -4.33 |
| Tax Burden | 1.00 | 0.99 | 1.01 |
| Interest Burden | 1.07 | 1.01 | 1.02 |
| Research & Development to Revenue | 0.00 | 12.76 | 0.47 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | -0.07 | 0.02 |
| Income Quality | 1.28 | 1.00 | 1.71 |
Currency in EUR